康方生物2024年新药销售收入同比增长25%
本报讯 （记者张文湘见习记者占健宇）3月30日，康方生物科技（开曼）有限公司（以下简称“康方生物”）公布2024年业绩。去年公司新药销售收入超20亿元，同比增长25%。核心双抗产品卡度尼利、依沃西均被纳入国家医保目录，预计2025年进入放量期。
2024年，康方生物新药开发继续推进，包括依沃西获批上市在内，全年新增3款新药获批，5项新适应症审评中；2款双抗共4项Ⅲ期临床获阳性结果，20项品种Ⅲ期研究进行中。此外，依沃西首个海外Ⅲ期研究（HARMONi）的数据将于今年年中公布，有望加速海外上市进程。
（文章来源：证券日报）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10